Echocardiographic score for the screening of cardiac amyloidosis with positive 99m technetium pyrophosphate scintigraphy result.
amyloidosis
echocardiography
strain
Journal
Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
06
04
2023
received:
02
02
2023
accepted:
12
05
2023
medline:
13
7
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
Speckle-tracking-derived strains in cardiac chambers may provide better solutions for transthyretin amyloid cardiomyopathy (ATTR-CM) screening. This study aimed to evaluate the efficacy of biventricular strain measurements using speckle tracking for screening We performed a retrospective analysis of transthoracic echocardiographic studies using vendor-independent speckle tracking analysis in older patients (≥65 years) who underwent The entire cohort (n = 89) was divided into two subgroups positive Our proposed echocardiographic screening tool for
Substances chimiques
Technetium Tc 99m Pyrophosphate
5L76I61H2B
Technetium
7440-26-8
Diphosphates
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
634-641Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Castaño A, Drachman BM, Judge D, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20:163-178.
Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015;278:126-144.
Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075.
Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16-26.
Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7-e22.
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404-2412.
González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585-2594.
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-1016.
Wizenberg TA, Muz J, Sohn YH, et al. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J. 1982;103:468-473.
Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076-1084.
Bokhari S, Castaño A, Pozniakoff T, et al. Tc-pyrophosphate scintigraphy for differentiating lightchain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195-201.
Tsutsui Y, Kubota T, Kato S, et al. Utility of 99mTc-pyrophosphate scintigraphy in diagnosing transthyretin cardiac amyloidosis in real-world practice. Circ Rep. 2019;1:277-285.
Inomata T, Tahara N, Nakamura K, et al. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm. ESC Heart Fail. 2021;8:2647-2659.
Tahara N, Lairez O, Endo J, et al. 99mTechnetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022;9:251-262.
Marume K, Takashio S, Nishi M, et al. Combination of commonly examined parameters is a useful predictor of positive 99mTc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis. Circ J. 2019;83:1698-1708.
Koyama J, Minamisawa M, Sekijima Y, et al. Role of echocardiography in assessing cardiac amyloidoses: a systematic review. J Echocardiogr. 2019;17:64-75.
Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018;5:27-35.
Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1-64.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314.
Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277-313.
Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018;19:591-600.
Nagata Y, Takeuchi M, Mizukoshi K, et al. Intervendor variability of two-dimensional strain using vendor-specific and vendor-independent softwar. J Am Soc Echocardiogr. 2015;28:630-641.
Il'Giovine ZJ, Mulder H, Chiswell K, et al. Right ventricular longitudinal strain reproducibility using vendor-dependent and vendor-independent software. J Am Soc Echocardiogr. 2018;31:721-732.
Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6:1066-1072.
Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880-889.
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25:e1-e39.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981;63:188-196.
Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737-743.
Picano E, Pinamonti B, Ferdeghini EM, et al. Two-dimensional echocardiography in myocardial amyloidosis. Echocardiography. 1991;8:253-259.
Pagourelias ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10:e005588.
Koyama J, Ikeda S, Ikeda U. Echocardiographic assessment of the cardiac amyloidoses. Circ J. 2015;79:721-734.
Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442-1448.
Minamisawa M, Koyama J, Sekijima Y, et al. Comparison of the standard and speckle tracking echocardiographic features of wild-type and mutated transthyretin cardiac amyloidoses. Eur Heart J Cardiovasc Imaging. 2016;17:402-410.
Usuku H, Takashio S, Yamamoto E, et al. Usefulness of relative apical longitudinal strain index to predict positive 99m Tc-labeled pyrophosphate scintigraphy findings in advanced-age patients with suspected transthyretin amyloid cardiomyopathy. Echocardiography. 2020;37:1774-1783.
Cuddy SA, Datar Y, Ovsak G, et al. Optimal echocardiographic parameters to improve the diagnostic yield of Tc-99m-bone avid tracer cardiac scintigraphy for transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging. 2022;15:e014645.
Bodez D, Ternacle J, Guellich A, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016;23:158-167.
Uzan C, Lairez O, Raud-Raynier P, et al. al. Right ventricular longitudinal strain: a tool for diagnosis and prognosis in light-chain amyloidosis. Amyloid. 2018;25:18-25.
Usuku H, Takashio S, Yamamoto E, et al. Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy. J Cardiol. 2022;80:56-63.
Child JS, Krivokapich J, Abbasi AS. Increased right ventricular thickness on echocardiography in amyloid infiltrative cardiomyopathy. Am J Cardiol. 1979;44:1391-1395.